The Nitric Oxide/cGMP Signaling Pathway in Pulmonary Hypertension

Heterogeneity of pulmonary endothelial cyclic nucleotide response toPseudomonas aeruginosaExoY infection

“…cAMP and cGMP are both constitutively formed by transmembrane and soluble adenylyl or guanylyl cyclases in many cell types (36,48,49), including pulmonary endothelium (29,43), and hydrolyzed by specific phosphodiesterases (PDEs) (7,19). The presence or absence of these PDEs plays a large role in the relative abundance of the cNMPs at a given time.…”

Sildenafil for the Treatment of Pulmonary Hypertension in Pediatric Patients

“…Interactions between cGMP and cGMP-dependent protein kinases subsequently result in vasodilation [43]. Further understanding of this pathway has led to clinically important treatment options including inhaled NO (iNO) administration and drugs such as sildenafil that inhibit metabolism of cGMP.…”

Sildenafil Potentiates Bone Morphogenetic Protein Signaling in Pulmonary Arterial Smooth Muscle Cells and in Experimental Pulmonary Hypertension

“…6 The production of endothelial nitric oxide and the stimulation of smooth muscle-soluble guanylyl cyclase to generate cGMP is an important vasodilator and antiproliferative pathway in the pulmonary circulation. 7 Phosphodiesterase type 5 (PDE5) is largely responsible for the hydrolysis of cGMP and is expressed at a high level in the pulmonary circulation compared with systemic vessels. 8 Decreased endothelial nitric oxide production and increased PDE5 expression and activity are 2 important pathologic features of PAH.…”